Company intelligence / Profile preview
Senhwa Biosciences, Inc.
New Taipei City, New Taipei City, Taiwansenhwabio.com ↗
- Ownership
- Public · 6492
- Development stage
- Other
01
Overview
Recent positive clinical data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in Basal Cell Carcinoma showed three patients achieved partial response (PR) and ten had stable disease (SD). Two patients had progression-free survival exceeding 21 months. The drug demonstrated superior tolerability and disease control potential compared to current first- and second-line therapies.[2][8]
- Therapeutic areas
- OncologyRare DiseasesInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Financials
- Market cap
- $101.3M
- Total revenue
- $32.7K
- Enterprise value
- $82.4M
Beyond the preview
Go deeper on Senhwa Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Senhwa Biosciences, Inc..